New dosing strategy aims to make liver cancer drug easier to tolerate
NCT ID NCT05622136
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to see how many can complete four treatment cycles, while also tracking side effects, quality of life, and cancer control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Regorafenib (a targeted cancer drug taken as pills)
What this could lead to
If successful, this could offer a better-tolerated way to give regorafenib, helping more patients complete treatment and potentially control their liver cancer longer.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drug can still cause side effects, and it is not a cure—cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICESP - Instituto do Câncer do Estado de São Paulo
São Paulo, São Paulo, 01246-000, Brazil